Because nothing says "safe" like an FDA stamp of approval. -Ed.
MassHighTech, June 16, 2011
The U.S. Food and Drug Administration is reviewing a vaccine for invasive meningococcal disease developed by Novartis Vaccines and Diagnostics, the Cambridge division of Switzerland-based Novartis, for accepted use in infants and toddlers from two months to two years old. The immunization, called Menveo, is already approved in the U.S. for two to 55-year-olds.
Menveo just received FDA approval in January for children two to 10 years old. In the European Union, the vaccine is approved for people from age 11 and up, with Novartis seeking European Medicines Agency approval for infants and children soon, the company said.